Pevonedistat

Synopsis, Chemistry

DEVELOPMENTS

4 Drug(s) in Development

4 Drug(s) in Development

DIGITAL CONTENT

3 News

3 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Mln4924, Mln-4924, 905579-51-3, Mln 4924, Pevonedistat (mln-4924), ((1s,2s,4r)-4-(4-(((s)-2,3-dihydro-1h-inden-1-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate

Molecular Formula

C₂₁H₂₅N₅O₄S

Molecular Weight

443.5 g/mol

InChI Key

MPUQHZXIXSTTDU-QXGSTGNESA-N

FDA UNII

S3AZD8D215

Pevonedistat is a small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. Pevonedistat binds to and inhibits NAE, which may result in the inhibition of tumor cell proliferation and survival. NAE activates Nedd8 (Neural precursor cell expressed, developmentally down-regulated 8), an ubiquitin-like (UBL) protein that modifies cellular targets in a pathway that is parallel to but distinct from the ubiquitin-proteasome pathway (UPP). Functioning in diverse regulatory activities, proteins conjugated to UBLs like Nedd8 typically are not targeted for proteasomal degradation.

1 2D Structure

Pevonedistat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate

2.1.2 InChI

InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1

2.1.3 InChI Key

MPUQHZXIXSTTDU-QXGSTGNESA-N

2.1.4 Canonical SMILES

C1CC2=CC=CC=C2C1NC3=C4C=CN(C4=NC=N3)C5CC(C(C5)O)COS(=O)(=O)N

2.1.5 Isomeric SMILES

C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N

2.2 Other Identifiers

2.2.1 UNII

S3AZD8D215

2.3 Synonyms

2.3.1 MeSH Synonyms

1. ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulfamate

2. ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulphamate

3. 4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl Methyl Sulfamidate

4. Mln-4924

5. Mln4924

2.3.2 Depositor-Supplied Synonyms

1. Mln4924

2. Mln-4924

3. 905579-51-3

4. Mln 4924

5. Pevonedistat (mln-4924)

6. ((1s,2s,4r)-4-(4-(((s)-2,3-dihydro-1h-inden-1-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulfamate

7. Mln-4924003

8. S3azd8d215

9. 905579-51-3 (free Base)

10. Pevonedistat (usan)

11. Pevonedistat [usan]

12. [(1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl]methyl Sulfamate

13. Sulfamic Acid [(1s,2s,4r)-4-[4-[[(1s)-2,3-dihydro-1h-inden-1-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl Ester

14. ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulfamate

15. Sulfamic Acid, ((1s,2s,4r)-4-(4-(((1s)-2,3-dihydro-1h-inden-1-yl)amino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Ester

16. Pevonedistat [usan:inn]

17. Pevonedistatum

18. Unii-s3azd8d215

19. 3gzn

20. ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl Sulfamate

21. B39

22. Pevonedistat; Mln4924

23. Pevonedistat [inn]

24. ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulphamate

25. Mls006010830

26. Pevonedistat [who-dd]

27. Schembl192875

28. Tak924

29. Chembl1231160

30. Chebi:95028

31. Gtpl12117

32. Tak-924

33. Chebi:145535

34. Dtxsid701022549

35. Ex-a1472

36. Bdbm50285607

37. Nsc793435

38. Zinc58660702

39. Akos025401927

40. Cs-0348

41. Db11759

42. Nsc-793435

43. Ncgc00345794-02

44. Ncgc00345794-07

45. Ncgc00345794-10

46. [(1s,2s,4r)-4-[4-[[(1s)-2,3-dihydro-1h-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl Sulfamate

47. [(1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl]methyl Sulfamate

48. 4-(4-((1s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl Methyl Sulfamidate

49. Ac-27394

50. Hy-70062

51. Smr004701757

52. D10413

53. Brd-k67844266-001-01-3

54. Q27166792

55. ((1s,2s,4r)-4-(4-(((1s)-2,3-dihydro-1h-inden-1-yl)amino(-7h-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulfamate

56. ((1s,2s,4r)-4-(4-((s)-2,3-dihydro-1h-inden-1-ylamino)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl Sulfamate

57. ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]-pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl Sulfamate

58. [(1s,2s,4r)-4-[4-[[(1s)-2,3-dihydro-1h-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxy-cyclopentyl]methyl Sulfamate

2.4 Create Date

2007-08-27

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₅N₅O₄S
Molecular Weight	443.5 g/mol
XLogP3	1.7
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Exact Mass	443.16272547 g/mol
Monoisotopic Mass	443.16272547 g/mol
Topological Polar Surface Area	141 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	734
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of acute myeloid leukaemia, Treatment of myelodysplastic syndromes

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)